Increased activation of Stat5 has previously been demonstrated to induce SMN expression (84) and pharmacological compounds that increase Stat5 improve disease phenotypes in SMA cellular and animal models (85,86). This evidence concerns the gene STAT5A and proximal spinal muscular atrophy.